Efficacy of Risankizumab on Symptoms in Patients With Scalp Psoriasis in a Post-Hoc Analysis of the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16

Main Article Content

Eingun James Song
Frontier Dermatology, Mill Creek, WA, USA

Phoebe Rich
Oregon Dermatology and Research Center, Portland, OR, USA

Navid Ezra
California Dermatology Institute, Ventura, CA, USA

Harrison Nguyen
Harrison Dermatology & Research Group, Missouri City, TX, USA; University of Houston College of Medicine, Houston, TX, USA; Baylor College of Medicine, Houston, TX, USA

Priya S. Mathur
AbbVie Inc., North Chicago, IL, USA

Brenton Bialik
AbbVie Inc., North Chicago, IL, USA

Chenyang Duan
AbbVie Inc., North Chicago, IL, USA

Richard Ta
AbbVie Inc., North Chicago, IL, USA

Toni Anschutz
AbbVie Inc., North Chicago, IL, USA

Lindsay Ackerman
Medical Dermatology Specialists, Phoenix, AZ, USA

Keywords

Risankizumab, scalp psoriasis

References

1. Augustin M, et al. Br J Dermatol. 2019;181(2):358–65.

2. Merola JF, et al. Clin Exp Dermatol. 2016;41(5):486–9.

3. Egeberg A, et al. BMC Dermatol. 2020;20:3.

4. Larsabal M, et al. Br J Dermatol. 2019;180(3):647–56.

5. Song EJ, et al. Presented at the Society for Investigative Dermatology (SID 2025) May 7–10, 2025, San Diego, CA.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/57ey8s02

Article Details

How to Cite
1.
Efficacy of Risankizumab on Symptoms in Patients With Scalp Psoriasis in a Post-Hoc Analysis of the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16. J of Skin. 2025;9(6):s636. doi:10.25251/57ey8s02
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>